azd-1305
Small moleculeexperimental
Clinical trial activity
13 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00689039)
Timeline
Indications
Mechanism of action
- HERGBLOCKER
KCNH2 blocker
L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)
SCN5A blocker
L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)
Voltage-gated L-type calcium channel blocker
L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)OC(=O)NCCN1CC2CN(CCOc3ccc(C#N)cc3F)CC(C1)O2- Mol. weight
- 434.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545169 ↗
Also known as
- azd1305
- azd1305
- azd1305
- azd1305
- azd 1305
- azd-1305
- azd-1305
- azd-1305
- azd-1305
- tert-butyl (2-(7-(2-(4-cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non3-yl)ethyl)carbamate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00957437 | Phase 1 | Aug 1, 2009 | AstraZeneca, Parexel |
| NCT00935025 | Phase 1 | Jul 1, 2009 | AstraZeneca, California Clinical Trials |
| NCT00915356 | Phase 2 | May 1, 2009 | AstraZeneca |
| NCT00712465 | Phase 1 | Aug 1, 2008 | AstraZeneca |
| NCT00748982 | Phase 2 | Aug 1, 2008 | AstraZeneca |
| NCT00707551 | Phase 1 | Jul 1, 2008 | AstraZeneca, Parexel |
| NCT00738322 | Phase 1 | Jul 1, 2008 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT00689247 | Phase 1 | Apr 1, 2008 | AstraZeneca |
| NCT00643448 | Phase 2 | Mar 1, 2008 | AstraZeneca, Svendborg Hospital |
| NCT00689403 | Phase 1 | Feb 1, 2008 | AstraZeneca, Parexel |
| NCT00688831 | Phase 1 | Jan 1, 2008 | AstraZeneca |
| NCT00616629 | Phase 2 | Jan 1, 2008 | AstraZeneca, University of Helsinki |
| NCT00689039 | Phase 1 | Apr 1, 2007 | AstraZeneca |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 13 | 13 | 2 | 2007 |
| Parexel | For profit | 3 | 0 | 1 | 2008 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2009 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Svendborg Hospital | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Helsinki | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1